Form 4: Biogen Director Monish Patolawala Acquires Shares Through Compensation Plan

Biogen Director Monish Patolawala acquired 2,370 shares of common stock on June 17, 2025, as part of a compensation plan, increasing his total beneficial ownership to 3,710 shares.

Summary

• Monish D. Patolawala, a Director of Biogen Inc. (BIIB), reported an acquisition of common stock.
• The transaction occurred on June 17, 2025.
• Mr. Patolawala acquired 2,370 shares of Biogen common stock.
• The acquisition price was $0 per share, indicating that these shares were likely granted as part of an equity compensation plan.
• Following this transaction, Mr. Patolawala beneficially owns a total of 3,710 shares of Biogen common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even if through compensation, is generally viewed positively as it aligns management's interests with shareholders. The transaction being under a 10b5-1 plan also indicates a structured and pre-planned event.

Positives

• The acquisition of shares by a director, even if through compensation, generally aligns the director's interests with those of the shareholders.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged and structured approach to equity compensation, which can enhance transparency.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation. It does not provide insights into broader industry trends or competitive dynamics, but rather reflects standard corporate governance and compensation practices within the biotechnology sector.

Related Party Transactions

• The acquisition of common stock by a director from the issuer is inherently a related party transaction, specifically an equity compensation grant.

Stakeholder Impact

• Shareholders: The transaction increases the director's stake in the company, potentially strengthening alignment of interests between the board and shareholders.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this specific filing.

Key Dates

Keywords

Biogen, BIIB, Monish Patolawala, Director, SEC Form 4, Insider Transaction, Stock Acquisition, Equity Compensation, Rule 10b5-1